Therefore, our findings highlight NRG1 H2 and L3 residue’s interaction with ERBB3–D73 and their potential importance in developing novel NRG1–ERBB3 inhibitors for treating and inhibiting tumor progression in DMs-facilitated BC. This evidence concerns the gene ERBB3 and breast cancer.